- Home
- STTK vs PLRX Comparison
STTK vs PLRX Comparison
Compare STTK & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- PLRX
- Stock Information
- Founded
- STTK 2016
- PLRX 2015
- Country
- STTK United States
- PLRX United States
- Employees
- STTK N/A
- PLRX N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- PLRX Health Care
- Exchange
- STTK Nasdaq
- PLRX Nasdaq
- Market Cap
- STTK 112.6M
- PLRX 93.3M
- IPO Year
- STTK 2020
- PLRX 2020
- Fundamental
- Price
- STTK $1.98
- PLRX $1.59
- Analyst Decision
- STTK Hold
- PLRX Hold
- Analyst Count
- STTK 5
- PLRX 11
- Target Price
- STTK $3.00
- PLRX $3.93
- AVG Volume (30 Days)
- STTK 411.4K
- PLRX 608.9K
- Earning Date
- STTK 11-13-2025
- PLRX 11-06-2025
- Dividend Yield
- STTK N/A
- PLRX N/A
- EPS Growth
- STTK N/A
- PLRX N/A
- EPS
- STTK N/A
- PLRX N/A
- Revenue
- STTK $2,997,000.00
- PLRX N/A
- Revenue This Year
- STTK N/A
- PLRX N/A
- Revenue Next Year
- STTK N/A
- PLRX N/A
- P/E Ratio
- STTK N/A
- PLRX N/A
- Revenue Growth
- STTK N/A
- PLRX N/A
- 52 Week Low
- STTK $0.69
- PLRX $1.10
- 52 Week High
- STTK $2.71
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- STTK 48.57
- PLRX 54.33
- Support Level
- STTK $1.72
- PLRX $1.45
- Resistance Level
- STTK $2.71
- PLRX $1.70
- Average True Range (ATR)
- STTK 0.22
- PLRX 0.09
- MACD
- STTK -0.09
- PLRX 0.02
- Stochastic Oscillator
- STTK 25.05
- PLRX 60.70
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.